Top-line findings from the ICESECRET clinical trial (NCT02399124) featuring the ProSense Cryoablation System for the ...

Five-year recurrence-free rates of 89.4% and 83.9% indicate durable disease control after ProSense cryoablation in localized ...

IceCure Medical Ltd. announced positive top-line results from its ICESECRET clinical trial of its ProSense cryoablation ...

A revolutionary non-surgical treatment developed at University Hospital Southampton is helping to transform care for kidney cancer.

For patients with obesity and atrial fibrillation (Afib), GLP-1 receptor agonist drugs may be the weight loss approach that ...

News, features, and commentary about cancer-related issues ...

A large national study in Denmark following nearly 1,900 patients over almost a decade found that a minimally invasive procedure called ablation is as effective as surgery for treating small kidney ...

Detailed price information for Icecure Medical Ltd Ord (ICCM-Q) from The Globe and Mail including charting and trades.

ICESECRET completed five-year follow-up after CT-guided ProSense cryoablation, with imaging-based surveillance for local recurrence and systematic capture of procedure-related complications.

Icecure Medical ( (ICCM)) just unveiled an announcement. On February 23, 2026, IceCure Medical announced it has completed five-year patient follow up in its ICESECRET clinical trial evaluating the ...